Why the study?
MRAs reduce mortality and hospitalization in HFrEF but remain underused despite guideline recommendations; identifying factors contributing to underuse is needed to inform quality improvement.
What are the rates and predictors of MRA prescription in patients with HFrEF eligible for therapy in UK primary care?
Cohort (n=24,135)
Yes
What are the rates and predictors of MRA prescription in patients with HFrEF eligible for therapy in UK primary care?
Absolute Event Rate: 55% vs 41%
Despite increasing prescription rates from 2014 to 2020, MRAs remain significantly underused in eligible UK patients with HFrEF, particularly among older patients and those with hypertension.
BACKGROUND AND AIMS: Mineralocorticoid receptor antagonists (MRAs) reduce mortality and hospitalisation in heart failure with reduced ejection fraction (HFrEF) but are underused, despite recommendation in key guidelines. Identifying the factors contributing to underuse and addressing adherence are key components of a learning health system. We aimed to evaluate MRA prescription in people with HFrEF who would benefit, based on the UK National Institute for Health and Care Excellence (NICE) HFrEF guideline. METHODS: We used clinical code lists to identify people with HFrEF in primary care electronic health record (EHR) data from The Health Improvement Network database. For each calendar year 2014-2020, we identified individuals who met the NICE guideline criteria for MRA therapy. We fitted mixed effects logistic regression models to determine the factors contributing to MRA prescription. RESULTS: Among 24 135 people with HFrEF studied between 2014 and 2020, 12 150 person-years were eligible for MRA treatment. The MRA prescription rate increased from 41% to 55%. MRA prescription was inversely associated with age (OR per 1 SD, 95% CI) (0.02 (0.01, 0.03)), increasing glomerular filtration rate (0.37 (0.25, 0.55)), hypertension (0.21 (0.40, 0.78)) and prescription of antihypertensives (0.03 (0.02, 0.07)). MRA prescription was associated with male gender (6.31 (3.20, 12.4)), dilated cardiomyopathy (25.9 (7.48, 89.4)), calendar year (2.17 (1.85, 2.54) per year after study start) and prescription of sacubitril/valsartan (214 (56, 823)). CONCLUSIONS: MRAs are underused in people with HFrEF in the UK. Although prescribing increased between 2014 and 2020, half of the cohort still did not receive the therapy. Older age, gender, comorbidities and co-prescriptions were linked to MRA underuse. Understanding the factors contributing to underprescribing at a population level should be used to inform quality improvement strategies.
No takes yet. Share an insight, caveat, or question.
Maclean et al. (2025) conducted a cohort in Heart failure with reduced ejection fraction (HFrEF) (n=24,135). Mineralocorticoid receptor antagonists (MRAs) was evaluated on MRA prescription rate.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: